Adwaiy Manerikar

Adwaiy Manerikar

Auto-generated profile, based on publicly available information

Adwaiy Manerikar

Department of Thoracic Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2020 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
ABAnkit Bharat
Ankit Bharat
MQMelissa Querrey
Melissa Querrey
NMNikolay S. Markov
Nikolay S. Markov
SKSamuel Kim
Samuel Kim
CKChitaru Kurihara
Chitaru Kurihara
GBG. R. Scott Budinger
G. R. Scott Budinger
Some patients with severe COVID-19 develop end-stage pulmonary fibrosis for which lung transplantation may be the only treatment.

5 July 2020 in Surgery
Verified
Journal Article
Closed access
BIBartlomiej Imielski
Bartlomiej Imielski
CKChitaru Kurihara
Chitaru Kurihara
AMAdwaiy Manerikar
Adwaiy Manerikar
SCSatya Chaudhary
Satya Chaudhary
SKSusan Kosterski
Susan Kosterski
ABAnkit Bharat
Ankit Bharat

16 November 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
ECEmily Cerier
Emily Cerier
CKChitaru Kurihara
Chitaru Kurihara
TKTaisuke Kaiho
Taisuke Kaiho
TTTakahide Toyoda
Takahide Toyoda
AMAdwaiy Manerikar
Adwaiy Manerikar
ABAnkit Bharat
Ankit Bharat
Growing evidence implicates complement in the pathogenesis of primary graft dysfunction (PGD). We hypothesized that early complement activation postreperfusion could predispose to severe PGD grade 3 (PGD-3) at 72 hours, which is associated with worst posttransplant outcomes. Consecutive lung transplant patients (n = 253) from January 2018 through June 2023 underwent timed open allograft biopsies at the end of cold ischemia (internal control) and 30 minutes postreperfusion. PGD-3 at 72 hours occurred in 14% (35/253) of patients; 17% (44/253) revealed positive C4d staining on postreperfusion allograft biopsy, and no biopsy-related complications were encountered. Significantly more patients with PGD-3 at 72 hours had positive C4d staining at 30 minutes postreperfusion compared with those without (51% vs 12%, P < .001). Conversely, patients with positive C4d staining were significantly more likely to develop PGD-3 at 72 hours (41% vs 8%, P < .001) and experienced worse long-term outcomes. In multivariate logistic regression, positive C4d staining remained highly predictive of PGD-3 (odds ratio 7.92, 95% confidence interval 2.97-21.1, P < .001). Hence, early complement deposition in allografts is highly predictive of PGD-3 at 72 hours. Our data support future studies to evaluate the role of complement inhibition in patients with early postreperfusion complement activation to mitigate PGD and improve transplant outcomes.

10 December 2020 in ASAIO Journal
Verified
Journal Article
Closed access
SWSatoshi Watanabe
Satoshi Watanabe
CKChitaru Kurihara
Chitaru Kurihara
AMAdwaiy Manerikar
Adwaiy Manerikar
STSanket Thakkar
Sanket Thakkar
MSMark Saine
Mark Saine
ABAnkit Bharat
Ankit Bharat
Venovenous extracorporeal membrane oxygenation (VV ECMO) is increasingly being used in the management of severe acute respiratory distress syndrome (ARDS). The Respiratory ECMO Survival Prediction (RESP) score is most commonly used to predict survival of patients undergoing ECMO. However, the RESP score does not incorporate renal and hepatic dysfunction which are frequently a part of the constellation of multiorgan dysfunction associated with ARDS. The Model for End-Stage Liver Disease (MELD) incorporates both liver and kidney dysfunction and is used in the risk stratification of liver transplant recipients as well as those undergoing cardiac surgery. The aim of this study was to assess the prognostic value of the MELD score in patients undergoing VV ECMO. Patients undergoing VV ECMO from 2016 to 2019 were extracted from our prospectively maintained institutional ECMO database and stratified based on MELD score. Baseline clinical, laboratory, and follow-up data, as well as post-ECMO outcomes, were compared. Of 71 patients, 50 patients (70.4%) had a MELD score <12 and 21 (29.6%) had a MELD score ≥12. The higher MELD score was associated with increased post-ECMO mortality but reduced risk of dialysis and tracheostomy. In multivariate analysis, higher MELD score (HR 1.35, 95% CI = 1.07–2.75), lower body surface area (HR 0.16, 0.04–0.65), RESP score (HR 0.75, 95% CI = 0.64–0.87), and platelet count (HR 0.99, 95% CI = 0.98–0.99), were significant predictors of postoperative mortality. We conclude that MELD score can be used complementarily to the RESP score to predict outcomes in patients with ARDS undergoing VV ECMO.

7 April 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
TTT. Toyoda
T. Toyoda
AMA. Manerikar
A. Manerikar
VKViswajit Kandula
Viswajit Kandula
ABA. Bharat
A. Bharat
CKC. Kurihara
C. Kurihara